Imaging Related Publications

Neurodegeneration / NeuroInflammation

K. Herholz, A. McMahon, J.C. Thompson, M. Jones, H. Boutin, J. Gregory, C.A. Parker and R. Hinz (2024) Quantitative imaging of regional cerebral protein synthesis in clinical Alzheimer's Disease by [11C]Leucine PET. Molecular Imaging and Biology, 26 977-985.

M. Vicente‑Rodríguez, R. Mancuso, A. Peris‑Yague, C. Simmons, NIMA Consortium, D. Gómez‑Nicola, V.H. Perry, F. Turkheimer, S. Lovestone, C.A. Parker and D. Cash (2023) Pharmacological modulation of TSPO in microglia/macrophages and neurons in a chronic neurodegenerative model of prion disease. Journal of Neuroin­flammation, 20 92-105.

D. Bochicchio, L. Christie, C.B. Lawrence, K. Herholz, C.A. Parker, R. Hinz and H. Boutin (2023) Measurement of protein synthesis rate in rat by [11C]Leucine PET imaging: Application to the TgF344‑AD model of Alzheimer’s Disease. Molecular Imaging and Biology, 25 596-605.

N.R. Livingston, V. Calsolaro, R. Hinz, J. Nowell, S. Raza, S. Gentleman, R.J. Tyacke, J. Myers, A.V. Venkataraman, R. Perneczky, R.N. Gunn, E.A. Rabiner, C.A. Parker, P.S. Murphy, P.B. Wren, D.J. Nutt, P.M. Matthews and P. Edison (2022) Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. Molecular Psychiatry, 27 2019-2029.

V. Calsolaro, P. Matthews, C. Donat, N. Livingston, G. Femminella, S. Silva Guedes, J. Myers, Z. Fan, R. Tyacke, A. Venkataraman, R. Perneczky, R. Gunn, E. Rabiner, S. Gentleman, C. Parker, P. Murphy, P. Wren, R. Hinz, M. Sastre, D. Nutt and P. Edison (2021) Astrocyte activation with late onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load. Molecular Psychiatry, 26 5848-5855.

M. Vicente-Rodríguez, N. Singh, F. Turkheimer, A. Peris-Yague, K. Randall, M. Veronese, C. Simmons, A.K. Haji-Dheere, J.Bordoloi, K. Sanders, R. O. Awais, E. Årstad, NIMA Consortium, D. Cash, C. A. Parker (2021) Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation. Brain Behaviour and Immunity, 96 154-167.

R. Mancuso, G. Fryatt, M. Cleal, J. Obst, E. Pipi, J. Monzón-Sandoval, E. Ribe, L. Winchester, C. Webber, A. Nevado, T. Jacobs, N. Austin, C. Theunis, K. Grauwen, E.D. Ruiz, A. Mudher, M. Vicente-Rodriguez, C.A. Parker, C. Simmons, D. Cash, J. Richardson, NIMA Consortium, D.N.C. Jones, S. Lovestone, D. Gómez-Nicola, V.H. Perry (2019) CSF1R inhibition by JNJ-40346527 blocks microglial proliferation and attenuates neurodegeneration in P301S mice. Brain 147 3243-3264.

R.J. Tyacke, J.F. Myers, A. Venkataraman, I. Mick, S. Turton, J. Passchier, S. Husbands, E.A. Rabiner, R.N. Gunn, P. Murphy, C.A. Parker and D.J. Nutt (2018) Evaluation of 11C-BU99008, a positron emission tomography ligand for the Imidazoline2 binding site in human brain. Journal of Nuclear Medicine, 59 1597-1602.

A. Venkataraman, N. Keat, JF Myers, S. Turton, I. Mick, R.N. Gunn, E.A. Rabiner, J. Passchier, C.A. Parker, R.J. Tyacke and D.J. Nutt (2018) First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site. EJNMMI Research 8 71-77.

C.A. Parker, E.A. Rabiner, R.N. Gunn, G. Searle, L. Martarello, R. Comley, M. Davy, A.A. Wilson, S. Houle, R. Mizrahi, M. Laruelle and V.J. Cunningham (2015) Human kinetic modelling of the 5-HT6 PET radioligand, 11C-GSK215083, and its utility for determining occupancy of the 5HT6 and 5HT2A receptors with SB742457. Journal of Nuclear Medicine 56 1901-1909.

D.R. Quelch, V. De Santis, A. Strege, J. Myers, L. Wells, D.Nutt, A. Lingford-Hughes, C.A.Parker and R. Tyacke (2015) Influence of agonist induced internalization on [3H]Ro15-4513 binding – An application to imaging fluctuations in endogenous GABA with positron emission tomography. Synapse 69 60-65.

D.R. Quelch, L. Katsouri, D.J. Nutt, C.A. Parker and R.J. Tyacke (2014) Imaging endogenous opioid peptide release with [11C]carfentanil and [3H]diprenorphine: influence of agonist-induced internalization. Journal of Cerebral Blood Flow and Metabolism 34 1604-1612.

D.R. Quelch, S.L. Withey, D.J. Nutt, R.J.Tyacke and C.A.Parker (2014) The influence of different cellular environments on PET radioligand binding: An application to D2/3-dopamine receptor imaging. Neuropharmacology 85 305-313.

C.A. Parker, N. Nabulsi, D. Holden, S-f Lin, T. Cass, D. Labaree, S Kealey, A.D. Gee, S.M. Husbands, D. Quelch, R.E. Carson, D.J. Nutt, Y. Huang and R.J. Tyacke (2014) Evaluation of [11C]BU99008, a Positron Emission Tomography ligand for the imidazoline2 binding sites in Rhesus brain. Journal of Nuclear Medicine 55 838-844.

N.J. Kalk, D.R. Owen, R.J. Tyacke, R. Reynolds, E.A. Rabiner, A.R. Lingford-Hughes and C.A. Parker (2013) Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET? Synapse 67 909-912.

S. Kealey, E.M. Turner, S.M. Husbands, C.A. Salinas, S. Jakobsen, R.J. Tyacke, D.J. Nutt, C.A. Parker and A.D. Gee (2013) Imaging imidazoline-I2 binding sites in porcine brain using [11C]BU99008. Journal of Nuclear Medicine, 54 139-144.

D.R. Quelch, C.A. Parker, D.J. Nutt, R.J. Tyacke and D. Erritzoe (2012) The influence of different cellular environments on [3H]DASB radioligand binding. Synapse, 66 1035-1039.

R.J. Tyacke, A. Fisher, E.S.J. Robinson, P. Grundt, E.M. Turner, SM. Husbands, A.L. Hudson, C.A. Parker and D.J. Nutt (2012) Evaluation and initial in vitro and ex vivo characterisation of the potential positron emission tomography ligand, BU99008, for the Imidazoline2 binding site. Synapse, 66 542-551.

D.R. Owen, A.J.Yeo, R.N. Gunn, K. Song, G. Wadsworth, A. Lewis, C. Rhodes, D.J. Pulford, I. Bennacef, C.A. Parker, P.L. StJean, L.R. Cardon, V.E. Mooser, P.M. Matthews, E.A. Rabiner and J. Rubio (2012) An 18kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. Journal of Cerebral Blood Flow and Metabolism, 32 1-5.

C.A. Parker, R.N. Gunn, E.A. Rabiner, M. Slifstein, R. Comley, C. Salinas, C.N. Johnson, S. Jakobsen, S. Houle, M. Laruelle, V.J. Cunningham and L. Martarello (2012) Radiosynthesis and characterisation of [11C]GSK215083 as a novel PET radioligand for the 5-HT6 receptor. Journal of Nuclear Medicine, 53 295-303.

D.R.J. Owen, A.J.M. Lewis, R. Reynolds, R. Rupprecht, D.A. Eser, M.R. Wilkins, I. Bennacef, D.J. Nutt and C.A. Parker (2011) Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse, 65 257-259.

V.W. Pike, S. Taliani, T.G. Lohith, D.R.J. Owen, I. Pugliesi, E. Da Pozzo, J. Hong, S.S. Zoghbi, R.N. Gunn, C.A. Parker, E.A. Rabiner, M. Fujita, R.B. Innis and C.Martini (2011) Evaluation of novel N1-2- Methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype. Journal of Medicinal Chemistry, 54 366-373.

D.R. Owen, R.N. Gunn, E.A. Rabiner, I. Bennacef, M. Fujita, W.C. Kreisl, R.B. Innis, V.W. Pike, R. Reynolds, P.M. Matthews and C.A. Parker (2011) Mixed affinity binding in humans with 18 kDa translocator protein (TSPO) ligands. Journal of Nuclear Medicine, 52 24-32.

D.R. Owen, O.W. Howell, S.P. Tang, L.A. Wells, I. Bennacef, M. Bergstrom, R.N. Gunn, E.A. Rabiner, M.R. Wilkins, R. Reynolds, P.M. Matthews and C.A. Parker (2010) Two binding sites for [3H]PBR28 in human brain: Implications for TSPO PET imaging of neuroinflammation. Journal of Cerebral Blood Flow and Metabolism, 30 1608-1618.

A.D. Gee, L. Martarello, J. Passchier, M. Wishart, C. Parker, J. Matthews, R. Comley, R. Hopper and R. Gunn (2008) Synthesis and evaluation of [11C]SB-207145 as the first in vivo serotonin 5-HT4 receptor radioligand for PET imaging in man. Current Radiopharmaceuticals, 1 110-114.

C.A. Parker, J.C. Matthews, R.N. Gunn., L. Martarello, V.J. Cunningham, D.M.F. Dommett, S.T. Knibb, D. Bender, S. Jakobson and A.D. Gee (2005) The in vitro affinities of R(-)- and S(+)-rolipram for PDE4 predict their in vivo behaviour in the porcine brain with PET. Synapse, 55 270-279.

Respiratory

P.T. Lukey, C. Coello, R.N. Gunn, C.A. Parker, F.J. Wilson, A. Saleem, N. Garman, M. Costa, S. Kendrick, M. Onega, A.K. Ombe, A. Listanco, J. Davies, J. Ramada-Magalhaes, S. Moz, W.A. Fahy, T.M. Maher, G. Jenkins, J.Passchier and R.P. Marshall (2020) [18F]FB-A20FMDV2 PET ligand quantifies αvβ6 in the lungs of healthy, Idiopathic Pulmonary Fibrosis and Connective Tissue Disease related fibrotic interstitial lung disease individuals (PETAL Study). European Journal of Nuclear Medicine and Molecular Imaging, 47 967-979.

M. Onega, C.A. Parker, C. Coello, G. Rizzo, N. Keat, J. Ramada-Magalhaes, S. Moz, S.P. Tang, C. Plisson, L. Wells, S. Ashworth, P. Szeto, R.J. Slack, G. Vitulli, F.J. Wilson, R. Gunn, P.T. Lukey and J. Passchier (2020) Evaluation of [18F]FB-A20FMDV2 as a selective marker for αVβ6 integrin using positron emission tomography in vivo. European Journal of Nuclear Medicine and Molecular Imaging, 47 958-966.

N. Keat, J. Kenny, K. Chen, M. Onega, N. Garman, R.J. Slack, C.A. Parker, R. Lumbers, W. Hallett, A. Saleem, J. Passchier and P.T. Lukey (2018) A First time in human, microdose, Positron Emission Tomography study of the safety, immunogenicity, biodistribution and radiation dosimetry of 18F-FB-A20FMDV2 for imaging the integrin αvβ6. Journal of Nuclear Medicine Technology, 46 136-143.

Oncology

A.C. Bashi, C.A.Parker, A.Saleem, J.-F. Salazar, C. Salinas, S.R. Morris, R. Kumar, H. Gabra and E. Stronach (2015) Use of a translational approach for predicting the clinical utility of the AKT inhibitor, GSK2141795, in ovarian cancer. Oncotarget 6 41736-41749.

Methodology

R.N. Gunn, S. Summerfield, C. Salinas, K. Read, Q. Guo, C.A. Parker, G. Searle, P. Jeffrey and M. Laruelle (2012) Combining PET biodistribution and equilibrium eialysis assays to assess the free brain concentration and BBB transport of CNS drugs. Journal of Cerebral Blood Flow and Metabolism, 32 874-883.

G.C. Shearman, G.S. Attard, A.N. Hunt, S. Jackowski, M. Baciu, S.C. Sebai, X. Mulet, J.A. Clarke, R.V. Law, C. Plisson, C.A. Parker, A. Gee, O. Ces and R.H. Templer (2007) Using membrane stress to our advantage. Biochemical Society Transactions, 35, 498-501.

M. Baciu, S.C. Sebai, O. Ces, X. Mulet, J.A. Clarke, G.C. Shearman, R.V. Law, R.H. Templer, C. Plisson, C.A. Parker and A.Gee (2006) Degradative transport of cationic amphiphilic drugs across phospholipid bilayers. Philosophical Transactions of the Royal Society A, 364, 2597-2614.

V.J. Cunningham, C.A. Parker, E.A. Rabiner, A.D. Gee and R.N. Gunn (2005) PET studies in drug development: Methodological considerations. Drug Discovery Today, 2 311-315.

C.A. Parker, N.J. Anderson, E.S.J. Robinson, R. Price, R.J. Tyacke, S.M. Husbands, M.P. Dillon, R.M. Eglen, A.L. Hudson, D.J. Nutt, M.P. Crump and J. Crosby (2004) Harmane and harmalan are bioactive components of "Classical" Clonidine Displacing Substance. Biochemistry, 43, 16385-16392.

E.J. Cooper, A.L. Hudson, C.A. Parker and N.G. Morgan (2003) Effects of the b-carbolines, harmane and pinoline, on insulin secretion from isolated rat and human islets of Langerhans. European Journal of Pharmacology, 482, 189-196.

N.G. Morgan, E.J. Cooper, P.E. Squires, C.E. Hills, C.A. Parker and A.L. Hudson (2003) Comparative effects of efaroxan and b-carbolines on the secretory activity of rodent and human b-cells. Annals of the New York Academy of Sciences, 1009, 167-174.

Reviews

C.A. Parker, D.J. Nutt and R.J. Tyacke (2023) Imidazoline-I2 PET tracers in neuroimaging. International Journal of Molecular Sciences, 24 DOI: 10.3390/ijms24129787

P.M. Matthews, R. Coatney, H. Alsaid, B. Jucker, S. Ashworth, C. Parker and K. Changani (2013) Technologies: Preclinical imaging for drug development. Drug Discovery Today: Technologies,10 e343-e350.